NOTE. Data are no. (%) of patients, unless otherwise indicated. MSM, man who has sex with men; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
To the Editor-The emergence and transmission of antiretroviral (ARV) drug-resistant HIV infection is a clinically relevant global health issue [1] . Observational studies have confirmed the emergence of ARV drug resistance within the first 5 years of a universal ARV access program designed to administer generic, fixed-dose, twice-daily stavudine, lamivudine, and nevirapine in Thailand [2, 3] . This study aimed to determine the prevalence of ARV drug resistance among ARV-naive individuals with HIV infection of unknown duration to inform current decision-making recommendations for baseline drug resistance testing in resource-limited settings. All ARV-naive persons who received HIV-related medical care at Thammasat University Hospital (Pratumthani, Thailand), a tertiary care referral center, from 1 January 2005 through 31 December 2007 were prospectively enrolled, and consent was obtained from all study participants. Demographic, clinical, and laboratory data, inclusive of the HIV status and ARV use of the participants' identified sex partners, were obtained from standardized interviews and structured medical chart reviews. Third-party consent was subsequently obtained from identified sex partners for study participation and chart review. Adherence to ARV therapy was assessed by scheduled pill counts. Quantification of HIV RNA level by PCR (Roche Amplicor, version 1.5 [Roche Diagnostic Systems]) and determination of resistance profile by Trugene HIV-1 Genotyping Assay (Visible Genetics) were performed for patients who had HIV RNA levels 11000 copies/mL. Reverse transcriptase genotypic resistance was assessed by a method validated for HIV clade B [4] . We defined ARV drug resistance using the criteria established by the International AIDS Society-United States of America [5] .
The study cohort comprised 151 ARVnaive participants with HIV infection of unknown duration from 12 provinces in central Thailand ( ). Each of these 6 patients was infected with HIV with resistance to 2 ARV classes; K103N and M184V were the most common drug-resistance mutations. By contact tracing, each of these 6 participants identified sex partners who were receiving care for HIV infection at the study site (and not elsewhere); all 6 of these patients reported a single sex partner and reported no recent (i.e., within the previous 24 months) sexual encounters with a commercial sex worker. Each identified sex partner had documented nonadherence (i.e., !75% adherence) to therapy with stavudine, lamivudine, and nevirapine and treatment failure. Isolates obtained from each initial participant with ARV drugresistant infection had ARV drug resistance mutations that were similar to those found in isolates obtained from their identified sex partner. The median duration of ARV therapy among the identified sex partners was 9 months (range, 6-12 months).
Current International AIDS Society Guidelines recommend baseline ARV drug resistance testing for individuals with recent confirmation of HIV infection (i.e., within 1 year), but the temporal relationship between the duration of HIV infection and the confirmation of HIV infection is quite varied [6] . In addition, the annual prevalence of ARV drug-resistant infection at this site reached 6% in 2007, which is slightly below the prevalence at which resistance testing in ARV-naive patients is considered to be cost-effective (8%-10%) [7] . Although our data do not currently support routine drug resistance testing among all ARV-naive patients in this resource-limited setting, our findings suggest that national surveillance for ARV drug-resistant HIV infection is prudent for informing population-based recommendations. In addition, if HIV-infected patients with newly diagnosed infection who are receiving treatment in clinics identify ARV-experienced sex partners, it should indicate to health care providers that there is a patient-specific risk for ARV drug-resistant HIV infection. 
Use of Blood Culture Vials and Nucleic Acid Amplification for the Diagnosis of Pediatric Septic Arthritis
To the Editor-In a recent article about the bacteriological diagnosis of skin and skeletal system infections, Wilson and Winn [1] strongly advised against the inoculation of synovial fluid exudates into blood culture vials (BCVs) and the use of nucleic acid amplification methods for diagnosing septic arthritis. Wilson and Winn [1] are correct in that BCVs were primarily designed to maximize recovery of bacterial and fungal pathogens from blood samples, and no manufacturer recommends extending their use for the diagnosis of septic arthritis. Experience accumulated over the past 2 decades, however, has clearly demonstrated that the routine use of BCVs significantly enhances the recovery of Kingella kingae from joint fluid aspirate specimens obtained from young children [2, 3] . In 2 large studies (conducted in Israel and France) in which BCVs were routinely used for culturing synovial fluid aspirate specimens obtained from children aged !2 years [2] and !3 years [3] , respectively, this emerging pediatric pathogen was isolated in one-half of specimens obtained from patients with culture-proven septic arthritis and represented the most common etiology of infection in this age group. Strikingly, routine solid media seeded with aliquots of the same synovial fluid specimens usually failed to grow the organism, but when positive BCVs were subcultured onto agar plates, K. kingae was recovered without difficulty. These findings indicate that pus exerts an inhibitory effect on the organism, and dilution of joint fluid exudates in a large volume of broth decreases the concentration of detrimental factors, improving the isolation of K. kingae.
In recent years, conventional and realtime PCR methods have further improved the detection of K. kingae and have firmly placed this fastidious organism as the most common cause of osteoarticular infections in children aged !3 years. In 2003, Moumile et al. [4] reported the recovery of K. kingae by culture of specimens from only 12 (67%) of 18 patients, whereas PCR results were positive for specimens from all of the patients. Rosey et al. [5] found that the sensitivity of the culture methods for detecting the organism was only 55% (12 of 22 cultures yielded positive results), compared with 95% (21 of 22 PCR results were positive) for the combined conventional and real-time PCR techniques. In a study by Verdier et al. [6] , K. kingae was recovered from 9 (14%) of 64 culture-positive specimens. Use of a PCR method for the remaining 107 culture-negative specimens revealed 15 additional cases of K. kingae infection. Recently, Chometon et al.
